Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham (UAB), Birmingham, AL, USA.
Division of Maternal-Fetal Medicine, UAB Department of Obstetrics and Gynecology, Birmingham, AL, USA.
J Matern Fetal Neonatal Med. 2024 Dec;37(1):2355293. doi: 10.1080/14767058.2024.2355293. Epub 2024 Jun 14.
Extracorporeal membrane oxygenation (ECMO) use in peripartum patients is rare, and there is a gap in the literature on the outcomes and guidance on using ECMO in peripartum patients. This study describes ECMO strategies our institution uses for peripartum patients and reports outcomes of ECMO use in peripartum patients with respiratory and/or cardiac failure.
A case series of all peripartum patients, defined as pregnant or up to 6 weeks after delivery of an infant >20 weeks gestation, from 2018 to 2023 from a single center requiring ECMO support. Patients were included if ECMO was initiated in the setting of cardiac, pulmonary, or combined failure. Patient demographics, operative details, ECMO data, and adverse outcomes for maternal, fetus, and neonates were all collected.
Eighteen patients met the inclusion criteria. The cohort had a mean maternal age of 30.7 years old and was racially diverse. A majority of this cohort tested positive for COVID-19 ( = 10, 55%). ECMO was a bridge to recovery for all patients, of whom 14 (78%) were discharged out of the hospital alive. No patients received transplantation or a durable mechanical device. The most common complications were infection (25%) and postpartum hemorrhage (22%).
ECMO use in peripartum patients in a single tertiary center was associated with a high survival rate. Furthermore, a strong multidisciplinary team, careful reevaluation of clinical trajectory, and consideration of complications and risks associated with using ECMO in peripartum patients are possible frameworks to use when challenged with critically ill peripartum patients.
围产期患者使用体外膜肺氧合(ECMO)的情况较为罕见,且有关围产期患者使用 ECMO 的结局和指导方面的文献存在空白。本研究描述了我们机构用于围产期患者的 ECMO 策略,并报告了因呼吸和/或心脏衰竭而使用 ECMO 的围产期患者的结局。
这是一项单中心的病例系列研究,纳入了 2018 年至 2023 年期间所有需要 ECMO 支持的围产期患者,定义为妊娠或分娩后 6 周内,且婴儿孕周>20 周。如果患者因心脏、肺部或合并衰竭而启动 ECMO,则将其纳入研究。收集患者的人口统计学、手术细节、ECMO 数据以及母婴和新生儿的不良结局。
18 名患者符合纳入标准。该队列的产妇平均年龄为 30.7 岁,种族多样。该队列中大多数患者(=10,55%)COVID-19 检测呈阳性。所有患者均通过 ECMO 恢复,其中 14 名(78%)患者出院时存活。没有患者接受移植或耐用的机械装置。最常见的并发症是感染(25%)和产后出血(22%)。
在一家三级中心,围产期患者使用 ECMO 与高存活率相关。此外,当面临重症围产期患者时,建立强大的多学科团队、仔细重新评估临床轨迹以及考虑围产期患者使用 ECMO 相关的并发症和风险,可能是使用 ECMO 的可行框架。